Exploring a new tumor suppressor to reduce breast cancer disparities in African American women.
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
This study is looking at a protein called SELENOF that helps fight breast cancer, especially in African American patients, to see how its lower levels might lead to higher death rates from the disease, with the goal of finding ways to boost this protein and improve treatment outcomes for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-10927355 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called SELENOF, which has been identified as a tumor suppressor in breast cancer. The study aims to understand how lower levels of SELENOF in African American patients contribute to higher breast cancer mortality rates. By examining genetic variations and protein expression in breast tumors, the researchers will develop therapeutic strategies to enhance SELENOF levels and improve patient outcomes. This approach includes laboratory experiments and potential clinical applications to address the racial disparities in breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with breast cancer, particularly those with lower levels of the SELENOF protein.
Not a fit: Patients who are not African American or those with breast cancer unrelated to SELENOF levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for African American women with breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting tumor suppressors to improve cancer treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Kastrati, Irida — Loyola University Chicago
- Study coordinator: Kastrati, Irida
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.